Kunal Nepali(Kunal Nepali) 副教授

Email
nepali@tmu.edu.tw
現   職
藥物科學學科 副教授

學經歷

學 歷

畢業學校與學位[修業時間]
Punjab Technical UniversityISF College of Pharmacy 博士
2008/08~2012/12
Punjab Technical UniversityISF College of Pharmacy 碩士
2006/08~2008/08
Uttar Pradesh Technical UniversityRajiv Academy For Pharmacy 學士
2002/07~2006/07

本校學術經歷

任職單位與職稱[起迄時間]
藥物科學學科副教授
2023/02/01~
藥物科學學科助理教授
2019/01/17~2023/01/31

本校兼職教學行政經歷

服務單位與職稱[起迄時間]
新藥研發產業博士學位學程副教授
2023/07/01 ~

其它經歷

任職單位與職稱[起迄時間]
Taipei Medical UniversityPost-Doctoral Research Fellow
2014/10/07~2019/01/16
Guru Nanak Dev UniversityAssistant Professor
2011/07/18~2014/05/30
Punjab Technical UniversityAssistant Professor
2008/08/27~2011/07/13

專長與研究領域

學門領域
學術專長
天然物
natural product chemistry
有機合成
organic synthesis

論文著作

清冊下載


1. 2024 Amandeep Thakur,Yi-Hsuan Chu,Chun-Hsu Pan,Kunal Nepali. Leveraging a rationally designed veliparib-based anilide eliciting anti-leukemic effects for the design of pH-responsive polymer nanoformulation . European Journal of Medicinal Chemistry .2024

2. 2024 Amandeep Thakur,Chun-Hsu Pan,Kunal Nepali. Recent Advances and Future Directions on Small Molecule VEGFR Inhibitors in Oncological Conditions . European Journal of Medicinal Chemistry .2024

3. 2024 First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity In Vitro and In Vivo . Journal of medicinal chemsitry .2024

4. 2024 Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress . Cancer Letters .2024

5. 2024 Spleen tyrosine kinase (SYK): an emerging target for the assemblage of small molecule antitumor agents . Expert Opinion on Investigational Drugs .2024

6. 2024 Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions . European Journal of Medicinal Chemistry .2024

7. 2024 Rationally Designed Febuxostat-Based Hydroxamic Acid and its pH-Responsive Nanoformulation Elicits Anti-Tumor Activity . European Journal of Medicinal Chemistry .2024

8. 2024 Scaffold hopping approaches for dual-target antitumor drug discovery: opportunities and challenges . Expert Opinion on Drug Discovery .2024

9. 2024 Syntheses of LSD1/HDAC Inhibitors with Demonstrated Efficacy against Colorectal Cancer: In Vitro and In Vivo Studies Including Patient-Derived Organoids . Journal of Medicinal Chemistry .2024

10. 2023 Rationally designed donepezil-based hydroxamates modulate Sig-1R and HDAC isoforms to exert anti-glioblastoma effects . European Journal of Medicinal Chemistry .2023

11. 2023 Prudent tactics to sail the boat of PARP inhibitors as therapeutics for diverse malignancies . EXPERT OPINION ON DRUG DISCOVERY .2023

12. 2023 Small molecule tractable PARP inhibitors: Scaffold construction approaches, mechanistic insights and structure activity relationship . Bioorganic chemistry .2023

13. 2023 Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer . Journal of Enzyme Inhibition and Medicinal Chemistry .2023

14. 2023 Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer . Journal of Enzyme Inhibition and Medicinal Chemistry .2023

15. 2023 Meet the Editorial Board Member - kunal nepali . Mini-Reviews in Medicinal Chemistry .2023 ;(23):2-2

16. 2023 N-Heterocycle based Degraders (PROTACs) manifesting anticancer efficacy: Recent Advances . Current drug targets .2023

17. 2022 The Role of Epigenetic Mechanisms in Autoimmune, Neurodegenerative, Cardiovascular, and Imprinting Disorders. . Mini Reviews in Medicinal Chemistry, 2022 .2022

18. 2022 Charanjit Kaur,Bhargavi Sharma,Kunal Nepali. Switch Pocket Kinase: An Emerging Therapeutic Target for the Design of Anticancer Agents . Anticancer agents in Medicinal chemistry .2022

19. 2022 Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment . Journal of Advanced Research .2022

20. 2022 Glioblastoma: Current Status, Emerging Targets, and Recent Advances . Journal of Medicinal Chemistry .2022

21. 2022 Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier . European Journal of Medicinal Chemistry .2022

22. 2022 Kunal Nepali,Ram Sharma,Sachin Sharma,Amandeep Thakur,Jing Ping Liou. Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal . Journal of biomedical science .2022

23. 2021 Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma . European Journal of medicinal chemistry .2021

24. 2021 A novel histone deacetylase inhibitor MPT0L184 dysregulates cell-cycle checkpoints and initiates unscheduled mitotic signaling . Biomedicine and Pharmacotherapy. .2021

25. 2021 Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends . Journal of biomedical sciences .2021

26. 2021 Emerging Role of Terpenoids for the Treatment of Cancer: A Review . Mini reviews in medicinal chemistry .2021

27. 2021 The HDAC/HSP90 Inhibitor G570 Attenuated Blue Light-Induced Cell Migration in RPE Cells and Neovascularization in Mice through Decreased VEGF Production . Molecules .2021

28. 2021 Ritu ojha,I-Chung Chen,Chien-Ming Hsieh,Kunal Nepali. Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent . Journal of medicinal chemistry .2021

29. 2020 Kunal Nepali,Ting-Yu Chang,Mei-Jung Lai,Kai-Cheng Hsu,Yun Yen,Tony Eight Lin. Purine/Purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors . European Journal of medicinal chemistry .2020

30. 2020 Navdeep Kaur,Yao-Ching Fang,Hsueh-Yun Lee,Arshdeep Singh,Kunal Nepali,Mei-Hsiang Lin. Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment . European Journal of medicinal chemistry .2020

31. 2020 Ritu Ojha,Kunal Nepali,Chun-Han Chen,Kuo-Hsiang Chuang,Tung-Yun Wu,Tony Eight Lin. Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo. . European Journal of Medicinal Chemistry .2020

32. 2020 Steering the antitumor drug discovery campaign towards structurally diverse indolines . Bioorganic Chemistry .2020 ;(0)

33. 2020 Kuei-Ju Cheng,Chien-Ming Hsieh,Kunal Nepali,Jing-Ping Liou. Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye . J Med Chem .2020

34. 2020 sachin sharma,Arshdeep singh,sahil sharma,Ram Sharma,kunal nepali,Jing Ping Liou. Tailored Quinolines Demonstrate Flexibility to Exert Antitumor Effects through Varied Mechanisms-A Medicinal Perspective . Anticancer agents in medicinal chemistry .2020

35. 2019 Nepali K,Lee HY,Liou JP. Nitro-Group-Containing Drugs. . J Med Chem .2019 ;(62):2851-2893

36. 2019 1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase . European journal of medicinal chemistry .2019 ;(162):612-630

37. 2019 Kunal Nepali, Lin MH,Chao MW, Peng SJ, Hsu KC, Lin TE. Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cells . Bioorganic paper .2019 ;(91):103119-103119

38. 2018 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC. . Eur J Med Chem. .2018 ;(150):667-677

39. 2018 (N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo. . J Med Chem .2018 ;(61):905-917

40. 2017 Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets . J Med Chem .2017 ;(60):527-553

41. 2017 Manroopraj Kaur,Amandeep Kaur,Suhani Mankotia, Harbinder Singh, Arshdeep Singh,Jatinder Vir Singh. Synthesis, screening and docking of fused pyrano[3,2-d]pyrimidine derivatives as xanthine oxidase inhibitor. . European journal of medicinal chemistry .2017 ;(131):14-28

42. 2017 Ring-opened tetrahydro-γ-carbolines display cytotoxicity and selectivity with histone deacetylase isoforms. . Eur J Med Chem .2017 ;(127):115-127

43. 2016 Sahil Sharma,Jagjeet Singh,Ritu Ojha,Harbinder Singh,Manpreet Kaur,Kunal Nepali. Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors . European Journal of Medicinal Chemistry .2016

44. 2016 Early investigational tubulin inhibitors as novel cancer therapeutics. . Expert Opin Investig Drugs .2016 ;(25):917-936

45. 2016 2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition. . Org Biomol Chem. .2016 ;(14):716-723

46. 2015 Harpreet S. Virdi,Sahil Sharma,Samir Mehndiratta,P. M. S. Bedi,Kunal Nepali. Design, synthesis and evaluation of 2, 4-diarylpyrano [3, 2-c] chromen-5 (4H)-one as a new class of non-purine xanthine oxidase inhibitors . Journal of Enzyme Inhibition and Medicinal Chemistry .2015

研究計畫

計畫名稱
113 點擊化學及鈴木偶合反應方法建構鎖定DNA損害修復路徑之小分子雙效抑制劑(1/3)
補助單位
國家科學及技術委員會

計畫名稱
113 「點擊化學及鈴木偶合反應方法建構鎖定DNA損害修復路徑之小分子雙效抑制劑」-延攬印度籍RAM SHARMA RAM SHARMA
補助單位
國家科學及技術委員會

計畫名稱
112 理性設計全新類型雙效PARP-SYK抑制劑作為抗癌試劑
補助單位
國家科學及技術委員會

計畫名稱
111 Development of a retinoic-base histone deacetylase inhibitor as early-stage AMD treatment
補助單位
國家科學及技術委員會

計畫名稱
111 利用聯芳、生物鹼、黃酮和香豆素的結構工程為特發性肺纖維化提供抗纖維化藥物
補助單位
國家科學及技術委員會

計畫名稱
110 標題:謹慎設計抗胃癌藥物:結構簡化方法、骨架躍遷策略以及對二氧化矽負載的質子酸/路易斯酸催化的多組分反應以產生關鍵中間體的詳盡探索
補助單位
科技部

計畫名稱
109 多靶點抗癌藥物之設計與合成(2/2)
補助單位
科技部

計畫名稱
108 多靶點抗癌藥物之設計與合成(1/2)
補助單位
科技部

計畫名稱
107 新聘教師研究補助
補助單位
臺北醫學大學